500165-24-2

Upstream product

• 181122-00-9 3,4-dihydro-4,4,6-trimethyl-2(1H)-quinolinone 
• 500165-25-3 7-bromo-1,4,4,6-tetramethyl-3,4-dihydro-1H-quinoline-2-one 
• 459810-97-0 3-formyl-6-trifluoromethoxy-1-phenyl boronic acid 
• 459811-02-0 7-bromo-4,4,6-trimethyl-3,4-dihydro-1H-quinoline-2-one 

Downstream Products

• 945039-15-6 C₂₇H₃₀F₃NO₄ 
• 932367-37-8 3-[3-(1,4,4,6-Tetramethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl)-4-trifluoromethoxy-phenyl]-acrylic acid 

Relevant academic research and scientific papers

RXR-LXR heterodimer modulators for the potential treatment of dyslipidemia

A number of RXR agonists were synthesized and screened in functional assays. The synthesis and the structure-activity relationship (SAR) within the series of compounds will be presented. Some in vivo data in rodent models for dyslipidemia and diabetes wil

N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases

The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia:

Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia

The present invention relates to compounds of Formula (I) which may be useful in the treatment of diseases, such as, metabolic disorders, dyslipidemia and/or hyperchloesterolemia: 1